Catch up on your JDD reading with highlights from the August issue, Special Focus: Psoriasis.
Strober, Bagel, and Lebwohl et al present Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study READ NOW
The Static Physician’s Global Assessment of Genitalia: A Clinical Outcome Measure for the Severity of Genital Psoriasis describes the development of the the sPGA-G scale, a clinical outcome measure for the assessment of genital psoriasis severity that accounts for the erythematous clinical presentation of genital psoriasis. READ NOW
In Methods for Imputing Missing Efficacy Data in Clinical Trials of Biologic Psoriasis, authors evaluate the effects of different data imputation methods on apparent secukinumab response rates. READ NOW
A Comparative Study to Evaluate Epidermal Barrier Integrity of Psoriasis Patients Treated With Calcipotriene/Betamethasone Topical Suspension Versus Betamethasone Dipropionate 0.05% Lotion, authors demonstrate that treatment of plaque psoriasis with a combination topical corticosteroid and calcipotriene product may result in greater preservation of the skin layers. READ NOW
Treatment of Inverse/Intertriginous Psoriasis: Updated Guidelines from the Medical Board of the National Psoriasis Foundation summarizes advantages to topical nonsteroidal, systemic, or phototherapy for extensive disease resistant to topicals and provides an updated consensus on inverse psoriasis therapy. READ NOW
Members ascertain stakeholder input on domain match and feasibility of multiple psoriasis instruments in International Dermatology Outcome Measures (IDEOM) Group 2016 New York Meeting: Meeting Summary and Data from the Psoriasis Working Group READ NOW
In Adalimumab in Chronic Plaque Psoriasis: A Clinical Guide, the authors provide a clinical guide for adalimumab and review existing data on the efficacy and safety of originator adalimumab in moderate–severe chronic plaque psoriasis in adult and pediatric patients. – READ NOW